Online citations, reference lists, and bibliographies.
← Back to Search

Liposomal Delivery Of Proteins And Peptides

Janani Swaminathan, C. Ehrhardt
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction: A number of delivery issues exist for biotech molecules including peptides, proteins and gene-based medicines that now make up over 60% of the drug pipeline. The problems comprise pharmaceutical ad biopharmaceutical issues. One of the common approaches to overcome these issues is the use of a carrier and liposomes as carriers have been investigated extensively over the last decade. Areas covered: The review has been discussed in terms of formulation and preclinical development studies and in vivo studies encompassing different delivery routes including parenteral, oral, buccal, pulmonary, intranasal, ocular and transdermal involving liposomes as carriers. Important research findings have been tabulated under each side heading and an expert opinion has been summarised for each delivery route. Expert opinion: The conclusion and expert opinion – conclusion sections discuss in detail troubleshooting aspects related to the use of liposomes as carriers for delivery of biopharmaceutical moieties and scrutinises the aspects behind the absence of a protein/peptide-containing liposome in market.
This paper references
10.1080/10611860802201134
Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery.
R. C. Bi (2008)
10.1529/BIOPHYSJ.105.079475
Calcitonin forms oligomeric pore-like structures in lipid membranes.
M. Diociaiuti (2006)
First report on clinical trial of inhalational interleukin-2 liposomes
10.1248/bpb.16.740
Influence of liposomes on tryptic digestion of insulin. II.
Y. Katô (1993)
10.1002/(SICI)1097-0142(19970401)79:7<1409::AID-CNCR19>3.0.CO;2-3
Interleukin‐2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases
C. Khanna (1997)
10.1016/J.JCONREL.2005.05.016
Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts.
Keon-Hyoung Song (2005)
10.1021/JS980235X
Application of surface-coated liposomes for oral delivery of peptide: effects of coating the liposome's surface on the GI transit of insulin.
K. Iwanaga (1999)
New ways to enter the blood stream: emerging strategies in transdermal drug delivery
N Jain (2004)
10.1152/ajpcell.1998.275.1.C56
Lasp-1 is a regulated phosphoprotein within the cAMP signaling pathway in the gastric parietal cell.
C. Chew (1998)
Hypoglycemic efficacy of chitosan-coated insulin liposomes after oral administration in mice.
Z. Wu (2004)
10.1016/S0196-9781(03)00033-0
Interactions of VIP with rigid phospholipid bilayers: implications for vasoreactivity
H. Önyüksel (2003)
10.1016/0264-410X(93)90265-Y
Immunoadjuvant activity of a liposomal IL-6 formulation.
A. Duits (1993)
10.1080/10611860701453653
Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery
A. Jain (2007)
Oral application of insulin encapsulated liposomes.
N. Das (1988)
10.1016/S1567-5769(01)00143-6
Interleukin-2 liposomes for primary immune deficiency using the aerosol route.
R. Ten (2002)
Protective effect of intravitreal injection
S Camelo (2012)
10.1016/J.BBAMEM.2006.11.017
Association of vasoactive intestinal peptide with polymer-grafted liposomes: structural aspects for pulmonary delivery.
B. Stark (2007)
10.1080/107175400266687
Transdermal delivery of insulin in mice by using lecithin vesicles as a carrier.
J. Guo (2000)
10.1016/j.ijpharm.2011.05.061
Encapsulation enhancement and stabilization of insulin in cationic liposomes.
Se-jin Park (2011)
10.1016/S0925-4439(98)00060-X
Pulmonary surfactant: functions and molecular composition.
J. Goerke (1998)
10.1248/BPB.16.457
Influence of liposomes on tryptic digestion of insulin.
Y. Katô (1993)
10.1007/978-1-4419-9745-6_14
Liposomes for Pulmonary Drug Delivery
Janani Swaminathan (2011)
10.1080/02652040010000334
Characterization of calcitonin-containing liposome formulations for intranasal delivery.
S. Law (2001)
10.1016/S0378-5173(98)00408-6
Pharmacodynamics of insulin in polyethylene glycol-coated liposomes.
A. Kim (1999)
10.1016/J.JCONREL.2006.03.014
Pulmonary delivery of insulin by liposomal carriers.
Y. Huang (2006)
10.1016/J.LFS.2004.05.027
The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer.
Z. Değim (2004)
10.1016/0024-3205(94)00425-0
Vasoactive intestinal peptide encapsulated in liposomes: effects on systemic arterial blood pressure.
X. Gao (1994)
10.1097/00006231-200006000-00104
Biodistribution of liposomal 131I-VIP in rat using gamma camera.
E. Refai (1999)
10.1016/S0006-3495(97)78861-1
Phosphatydylglycerol promotes bilayer insertion of salmon calcitonin.
J. Bradshaw (1997)
10.1006/CYTO.2000.0769
Biopharmaceutics of liposomal interleukin 2, oncolipin.
M. Neville (2000)
10.1097/00001813-200008000-00006
Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial
K. Skubitz (2000)
10.1016/0024-3205(95)02108-U
Encapsulation of vasoactive intestinal peptide into liposomes: effects on vasodilation in vivo.
H. Suzuki (1995)
10.1002/JSO.2930510110
Effect of liposomal interleukin‐2 on ascites‐forming rat hepatoma
H. Konno (1992)
10.1097/01.shk.0000215316.14489.e5
LIPOSOME-MEDIATED INTRAPERITONEAL INTERLEUKIN 10 GENE TRANSFER INCREASES SURVIVAL IN CECAL LITIGATION AND PUNCTURE MODEL OF SEPSIS
B. Kabay (2006)
10.1152/ajpregu.1998.275.1.R56
Vasodilation elicited by liposomal VIP is unimpeded by anti-VIP antibody in hamster cheek pouch.
H. Ikezaki (1998)
10.1016/j.ijpharm.2010.10.021
Noninvasive and persistent transfollicular drug delivery system using a combination of liposomes and iontophoresis.
K. Kajimoto (2011)
10.1097/00002371-200001000-00016
Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes.
E. Kedar (2000)
Mechanisms of vasodilatation elicited by VIP in sterically stabilised liposomes in vivo
F Sejourne (1997)
Properties of liposomes coated with hydrophobically modified chitosan in oral liposomal drug delivery.
J. Thongborisute (2006)
10.1152/ajpregu.1998.275.2.R588
Liposomal VIP attenuates phenylephrine- and ANG II-induced vasoconstriction in vivo.
H. Ikezaki (1998)
10.1007/s00262-005-0013-x
Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice
Dean Johnston (2005)
10.1210/ENDO-115-2-757
Liposome entrapment enhances the hypocalcemic action of parenterally administered calcitonin.
Masao Fukunaga (1984)
10.1080/10611860903012810
Characterization of cationic liposomes having IL-2 expressed on their external surface, and their affinity to cervical cancer cells expressing the IL-2 receptor
Teresa Corona-Ortega (2009)
Liposomes: quo vadis? PSTT 1998;1:19-31
G Storm (1998)
10.1016/S1461-5347(98)00007-8
Liposomes: quo vadis?
G. Storm (1998)
Glucose-sensing pulmonary delivery of human insulin to the systemic circulation of rats
E. Karathanasis (2007)
10.1167/IOVS.06-1305
Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal Peptide encapsulated in liposomes.
Laure Lajavardi (2007)
10.3109/02652049409040461
Liposomes as a carrier for oral administration of insulin: effect of formulation factors.
K. B. Choudhari (1994)
Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2.
A. Cabanes (1999)
10.1016/j.ijpharm.2009.10.031
Enhancement of nasal and intestinal calcitonin delivery by the novel Pheroid fatty acid based delivery system, and by N-trimethyl chitosan chloride.
L. D. du Plessis (2010)
Liposomal transfection of squamous carcinoma cells of the head and neck with IL-2 and B7 plasmids inducing an autologous immune response in vitro.
A. Mayer (2005)
10.1016/J.JCONREL.2007.01.010
Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen.
A. Vangala (2007)
10.3109/10611869808995862
The immunological co-adjuvant action of liposomal interleukin-2: the role of mode of localisation of the cytokine and antigen in the vesicles.
M. Gursel (1998)
10.4314/TJPR.V6I1.14641
Modified Transdermal Technologies: Breaking the Barriers of Drug Permeation via the Skin
R. Kumar (2007)
10.1016/J.BIOMATERIALS.2005.11.017
Heparin incorporating liposomes as a delivery system of heparin from PET-covered metallic stents: effect on haemocompatibility.
G. Koromila (2006)
10.1089/jop.2008.0074
Protective effect of intravitreal injection of vasoactive intestinal peptide-loaded liposomes on experimental autoimmune uveoretinitis.
Serge Camelo (2009)
10.1016/j.clim.2009.03.516
IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments.
Michelle R. Simpson-Abelson (2009)
Nebuliser: principle and performance
DR Hess (2000)
10.1016/0264-410X(90)90099-8
Enhancement of interleukin-2 activity by liposomes.
M. Joffret (1990)
10.1016/0009-3084(86)90077-0
Techniques for encapsulating bioactive agents into liposomes.
L. Mayer (1986)
10.1248/CPB.40.1569
Permeability of insulin entrapped in liposome through the nasal mucosa of rabbits.
Y. Maitani (1992)
10.1016/S0168-3659(02)00411-X
Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats.
H. Takeuchi (2003)
Vasodilatation elicited by liposomal VIP is unimpeded by anti-VIP antibody in hamster cheek pouch
H Ikezaki (1998)
10.1016/J.JCONREL.2006.04.004
Triggered release of inhaled insulin from the agglomerated vesicles: pharmacodynamic studies in rats.
E. Karathanasis (2006)
10.1002/jgm.1459
Gene therapy for psoriasis in the K14‐VEGF transgenic mouse model by topical transdermal delivery of interleukin‐4 using ultradeformable cationic liposome
J. Li (2010)
10.1016/S0378-5173(01)00579-8
Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat.
M. Kisel (2001)
10.1248/CPB.48.325
High entrapment of insulin and bovine serum albumin into neutral and positively-charged liposomes by the remote loading method.
S. Hwang (2000)
Inhaled insulin’s last gasp? Nat Biotech 2008;26:479-80
J. Kling (2008)
10.1002/jps.22054
Delivery of therapeutic proteins.
D. Pisal (2010)
Intranasal immunization with liposomes containing IL-2 enhances bacterial polysaccharide antigen-specific pulmonary secretory antibody response.
E. Abraham (1992)
10.1016/J.IJPHARM.2006.02.028
Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters.
I. Rubinstein (2006)
10.1248/BPB.19.1055
Dipalmitoylphosphatidylcholine liposomes with soybean-derived sterols and cholesterol as a carrier for the oral administration of insulin in rats.
K. Muramatsu (1996)
10.1080/026520400405660
Lipoinsulin encapsulated alginate-chitosan capsules: intestinal delivery in diabetic rats.
M. Ramadas (2000)
10.3109/10611861003733920
Cationic liposomes bearing IL-2 on their external surface induced mice leukocytes to kill human cervical cancer cells in vitro, and significantly reduced tumor burden in immunodepressed mice
R. Rangel-Corona (2011)
10.1166/JNN.2006.416
Oral administration of liposomal insulin.
I. T. Değim (2006)
10.1111/j.2042-7158.1997.tb06024.x
Nebulized Interleukin 2 Liposomes: Aerosol Characteristics and Biodistribution
C. Khanna (1997)
10.1016/S0168-3659(03)00160-3
Potentiality of double liposomes containing salmon calcitonin as an oral dosage form.
Kenji Yamabe (2003)
10.1016/j.jconrel.2009.10.027
Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure.
R. Suzuki (2010)
10.1006/IMMU.1994.1021
Liposomes for protein delivery: selecting manufacture and development processes.
A. Weiner (1994)
10.1152/AJPHEART.1996.271.1.H282
Encapsulation of VIP into liposomes restores vasorelaxation in hypertension in situ.
H. Suzuki (1996)
10.1081/LPR-100108460
ENHANCEMENT OF NASAL ABSORPTION OF CALCITONIN LOADED IN LIPOSOMES
S. Law (2001)
10.2217/17435889.1.3.297
Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential
M. Immordino (2006)
10.1016/j.peptides.2009.03.018
Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery
Ming Chen (2009)
Activity of liposomal interleukin-2 in vitro.
M. Adibzadeh (1992)
10.1080/08982100600993003
Stability of Protein-Encapsulating DRV Liposomes After Freeze-Drying: A Study with BSA and t-PA
Vassiliki Ntimenou (2006)
10.1097/00002371-199408000-00005
Delivery of Cytokines by Liposomes. II. Interleukin‐2 Encapsulated in Long‐Circulating Sterically Stabilized Liposomes: Immunomodulatory and Anti‐Tumor Activity in Mice
E. Kedar (1994)
Ocular and systemic bio-distribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats
S. Camelo (2007)
10.1016/S0378-5173(98)00392-5
Remote loading of diclofenac, insulin and fluorescein isothiocyanate labeled insulin into liposomes by pH and acetate gradient methods.
S. Hwang (1999)
Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: canine studies.
C. Khanna (1996)
10.1081/DDC-120021771
Double Liposomes: Hypoglycemic Effects of Liposomal Insulin on Normal Rats
Ken Katayama (2003)
10.1016/j.jconrel.2009.05.033
New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis.
Laure Lajavardi (2009)
10.1002/DDR.10162
In vivo efficacy of a novel double liposome as an oral dosage form of salmon calcitonin
Yoshinori Ebato (2003)
10.1038/nbt0508-479
Inhaled insulin's last gasp?
J. Kling (2008)
Efficient inducation of local and systemic antitumor immune response by liposome-mediated intratumoral co-transfer of interleukin-2 gene and interleukin-6 gene.
X. Cao (1999)
10.1007/s11095-005-9175-7
Novel Mucosal Insulin Delivery Systems Based on Fusogenic Liposomes
T. Goto (2005)
10.2337/diab.31.6.506
Prolonged Hypoglycemic Effect in Diabetic Dogs Due to Subcutaneous Administration of Insulin in Liposomes
R. W. Stevenson (1982)
10.1016/j.ejpb.2008.04.015
Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation.
B. Stark (2008)
10.1023/A:1020178304031
Biophysical Aspects of Using Liposomes as Delivery Vehicles
A. Ulrich (2002)
10.1023/A:1016009313548
Enteral Absorption of Insulin in Rats from Mucoadhesive Chitosan-Coated Liposomes
H. Takeuchi (2004)
10.1016/S0165-2478(97)02699-0
Interleukin-15 acts as an immunological co-adjuvant for liposomal antigen in vivo.
M. Gursel (1997)
The hypoglycaemic response of diabetic rats to insulin-liposomes.
J. Petkowicz (1990)
10.1016/j.jconrel.2009.03.019
Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery.
S. Chono (2009)
10.1097/01.aids.0000226952.49353.36
Therapy of ‘SHIV’ infected macaques with liposomes delivering antisense interleukin-4 DNA
N. Dhillon (2006)
10.1507/ENDOCRJ1954.26.337
Effects of oral administration of positively charged insulin liposomes on alloxan diabetic rats: preliminary study.
A. Hashimoto (1979)
Nebulizers: principles and performance.
D. Hess (2000)
10.1023/A:1016261321011
Cholate-Induced Disruption of Calcitonin-Loaded Liposomes: Formation of Trypsin-Resistant Lipid-Calcitonin-Cholate Complexes
A. Ariën (2004)
10.1211/0022357011775523
A novel and simple type of liposome carrier for recombinant interleukin‐2
E. Kanaoka (2001)
First report on immune potential of IL-2 encapsulated liposomes in individuals with immune deficiency and hepatitis-C
10.1081/DDC-120025872
Continuous Release of Interleukin-2 from Liposomal IL-2 (Mixture of Interleukin-2 and Liposomes) After Subcutaneous Administration to Mice
E. Kanaoka (2003)
10.1081/DDC-100102275
The relationship between the rigidity of the liposomal membrane and the absorption of insulin after nasal administration of liposomes modified with an enhancer containing insulin in rabbits.
K. Muramatsu (1999)
10.1002/jgm.1268
Topical delivery of interleukin‐13 antisense oligonucleotides with cationic elastic liposome for the treatment of atopic dermatitis
S. Kim (2009)
10.1038/cgt.2010.12
Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes in mice
P. Charoensit (2010)



This paper is referenced by
10.1007/978-1-4939-2543-8_11
Perspectives on Engineering Biobetter Therapeutic Proteins with Greater Stability in Inflammatory Environments
V. Ashutosh Rao (2015)
10.1002/adtp.201800085
Synthetic Vehicles for Encapsulation and Delivery of CRISPR/Cas9 Gene Editing Machinery
V. Carboni (2019)
10.2147/IJN.S242516
Conventional and Nanotechnology Based Approaches to Combat Chronic Obstructive Pulmonary Disease: Implications for Chronic Airway Diseases
Mehak Passi (2020)
10.1016/j.addr.2016.04.001
Lipid-based nanocarriers for oral peptide delivery.
Zhigao Niu (2016)
10.1016/j.msec.2017.10.004
Polyester micelles for drug delivery and cancer theranostics: Current achievements, progresses and future perspectives.
Yu Yi (2018)
10.3390/ijms19071987
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
L. Pickart (2018)
10.1016/j.yexcr.2019.111596
Exosome-delivered syndecan-1 rescues acute lung injury via FAK/p190RhoGAP/RhoA/ROCK/NF-κB signaling axis and glycocalyx enhancement.
C. Zhang (2019)
10.1016/J.JDDST.2017.06.018
Advances on the formulation of proteins using nanotechnologies
Irene Santalices (2017)
10.1007/s11095-014-1485-1
Enhancing the Buccal Mucosal Delivery of Peptide and Protein Therapeutics
Thiago Caon (2014)
10.2147/DDDT.S217211
Hydrogels For Peptide Hormones Delivery: Therapeutic And Tissue Engineering Applications
Mohsen Doostmohammadi (2019)
10.1021/bm500169p
Drug carriers for the delivery of therapeutic peptides.
A. W. Du (2014)
10.4155/tde.15.94
Recent advances in peptides for enhancing transdermal macromolecular drug delivery.
Renquan Ruan (2016)
Biodegradable Nanoparticles Based on Aliphatic Polyesters; Towards Targeted Intracellular Delivery of Protein Therapeutics
Neda Samadi (2014)
10.1038/ncomms12277
Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein–protein interaction module
Nambin Yim (2016)
10.1016/j.drudis.2014.09.020
Recent advances in controlled pulmonary drug delivery.
Zhenglin Liang (2015)
10.5530/RJPS.2014.2.3
Liposomal Drug Delivery System-A Review
Deepthi (2014)
10.4155/tde.14.5
Recent developments in protein and peptide parenteral delivery approaches.
Ashaben Patel (2014)
10.3109/10717544.2013.863526
Development and evaluation of a dry powder formulation of liposome-encapsulated oseltamivir phosphate for inhalation
Y. Tang (2015)
10.1017/S0954422414000225
Are intact peptides absorbed from the healthy gut in the adult human?
W. Miner-Williams (2014)
10.15171/bi.2016.26
Filgrastim (G-CSF) loaded liposomes: mathematical modeling and optimization of encapsulation efficiency and particle size
Farhad Kiafar (2016)
10.1039/c5cc03835a
Supramolecular nanofibers of self-assembling peptides and proteins for protein delivery.
H. Wang (2015)
Liposome: A Novel Carrier for Targeting Drug Delivery System
V. Patel (2020)
10.1016/j.colsurfb.2018.04.033
Optimizing liposomes for delivery of Bowman-Birk protease inhibitors - Platforms for multiple biomedical applications.
Graziella Anselmo Joanitti (2018)
10.3390/pharmaceutics12020115
The Stability Maintenance of Protein Drugs in Organic Coatings Based on Nanogels
Hongzhao Qi (2020)
10.1021/jacs.7b01214
Templated Self-Assembly of a Covalent Polymer Network for Intracellular Protein Delivery and Traceless Release.
Kingshuk Dutta (2017)
10.1007/978-3-642-27814-3_162-1
Resetting Skin Genome Back to Health Naturally with GHK
Loren Pickart (2015)
10.1080/17425247.2019.1621287
Novel therapeutic approaches for targeting TB and HIV reservoirs prevailing in lungs
Mrunal Jadhav (2019)
10.1021/acs.langmuir.5b01667
Capsosomes as Long-Term Delivery Vehicles for Protein Therapeutics.
J. Maina (2015)
Natural bacteriophages T4 and M13 down-regulates Hsp90 gene expression in human prostate cancer cells (PC-3) representing a potential nanoparticle againstcancer
S. Sanmukh (2017)
10.6000/1927-7229.2014.03.02.2
GHK, the Human Skin Remodeling Peptide, Induces Anti-Cancer Expression of Numerous Caspase, Growth Regulatory, and DNA Repair Genes
Loren Pickart (2014)
10.1039/C6CS00409A
Lipid-based nanovesicles for nanomedicine.
N. Grimaldi (2016)
10.1155/2014/151479
GHK and DNA: Resetting the Human Genome to Health
L. Pickart (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar